García-Flórez Luis J, Otero-Díez Jorge L, Encinas-Muñiz Ana I, Sánchez-Domínguez Luis
1 Hospital Universitario San Agustín, Avilés, Spain.
2 University of Oviedo, Oviedo, Spain.
Surg Innov. 2017 Aug;24(4):336-342. doi: 10.1177/1553350617700803. Epub 2017 Mar 29.
The aim of this study was to evaluate the feasibility, safety, perioperative morbidity, and short-term outcomes of the transanal minimally invasive surgery (TAMIS) technique.
This is a descriptive review of prospectively collected data from 32 consecutive patients who underwent TAMIS procedures in our colorectal unit over a 40-month period. GelPOINT Path port was used in all cases. Demographic data, indications, tumor characteristics, morbidity, and follow-up data were collected. Primary endpoints included feasibility, safety, perioperative morbidity, and resection quality.
Fifteen adenomas, 12 carcinomas, 1 gastrointestinal stromal tumor, and 1 neuroendocrine tumor were locally excised. Additionally, 3 pelvic abscesses were drained transanally using the TAMIS port. Mean distance from the anal verge was 5.6 ± 1.5 cm. Early postoperative complications occurred in 22%, with only one case of major complication (3.1%) requiring reoperation, and no postoperative mortality. Four carcinomas were understaged (33.3%) and 1 adenoma overstaged (6.7%) preoperatively. Three carcinomas were not suspected preoperatively (25%). Microscopic positive lateral margin was found in one case, and no affected deep margin was found. Fragmentation rate was 6.9%, 2 cases, both lesions over 20 cm. In cases of fit patients with high-risk carcinomas, 2 underwent immediate salvage surgery and another 2 refused and were treated with adjuvant radiotherapy. With a median follow-up of 26 months, the overall recurrence rate was 10.3%, 1 adenoma and 2 carcinomas.
TAMIS seems to be a safe and reproducible procedure for local excision of well-selected rectal lesions with low morbidity and good functional outcomes.
本研究旨在评估经肛门微创手术(TAMIS)技术的可行性、安全性、围手术期发病率及短期疗效。
这是一项描述性综述,对40个月期间在我们结直肠科连续接受TAMIS手术的32例患者的前瞻性收集数据进行分析。所有病例均使用GelPOINT Path端口。收集人口统计学数据、手术指征、肿瘤特征、发病率及随访数据。主要终点包括可行性、安全性、围手术期发病率及切除质量。
局部切除15例腺瘤、12例癌、1例胃肠道间质瘤及1例神经内分泌肿瘤。此外,使用TAMIS端口经肛门引流3例盆腔脓肿。距肛缘平均距离为5.6±1.5 cm。术后早期并发症发生率为22%,仅1例主要并发症(3.1%)需再次手术,无术后死亡病例。4例癌术前分期过低(33.3%),1例腺瘤术前分期过高(6.7%)。3例癌术前未被怀疑(25%)。1例镜下侧切缘阳性,未发现深部切缘受累。破碎率为6.9%,2例,均为病变超过20 cm。对于适合的高危癌患者,2例行即刻挽救性手术,另2例拒绝并接受辅助放疗。中位随访26个月,总复发率为l0.3%,1例腺瘤和2例癌。
TAMIS似乎是一种安全且可重复的手术方法,用于精心选择的直肠病变局部切除,发病率低且功能预后良好。